Five Prime Therapeutics, Inc.
11
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
36.4%
4 terminated/withdrawn out of 11 trials
60.0%
-26.5% vs industry average
0%
0 trials in Phase 3/4
117%
7 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
FPT155 in Patients With Advanced Solid Tumors
Role: lead
FPA150 in Patients With Advanced Solid Tumors
Role: lead
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
Role: lead
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer
Role: lead
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
Role: lead
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Role: lead
Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis Subjects
Role: lead
An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer
Role: lead
Study of FP-1039 in Subjects With Endometrial Cancers
Role: lead
Safety Study of FP-1039 To Treat Cancer
Role: lead
Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor
Role: lead
All 11 trials loaded